Everimmune
French tech company | Builders Republic
About
Biotech company developing living biotherapeutic products (LBPs) targeting the oncology microbiome — lead candidate Oncobax AM (Akkermansia muciniphila oral strain) designed to restore immunotherapy response in non-small cell lung cancer patients.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Venture Round
- Founded
- 2016
- City
- VILLEJUIF
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 5.0 M€ raised since 2020
Funding rounds
- Venture Round — 2021
Investors
- Omega Funds